Go Pro
→ Oxford Club Analyst’s Urgent AI Warning (From The Oxford Club) (Ad)tc pixel Free KLDO Stock Alerts

Kaleido Biosciences (KLDO) Competitors

Kaleido Biosciences logo
Compare

KLDO vs. MVLA, PRST, DMN, ICCT, and GROM

Should you buy Kaleido Biosciences stock or one of its competitors? MarketBeat compares Kaleido Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kaleido Biosciences include Movella (MVLA), Presto Automation (PRST), Grafiti (DMN), iCoreConnect (ICCT), and Grom Social Enterprises (GROM). These companies are all part of the "computer software" industry.

How does Kaleido Biosciences compare to Movella?

Kaleido Biosciences (NASDAQ:KLDO) and Movella (NASDAQ:MVLA) are both small-cap computer software companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

81.6% of Kaleido Biosciences shares are held by institutional investors. Comparatively, 40.9% of Movella shares are held by institutional investors. 9.0% of Kaleido Biosciences shares are held by insiders. Comparatively, 20.0% of Movella shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Kaleido Biosciences' average media sentiment score of 0.00 equaled Movella'saverage media sentiment score.

Company Overall Sentiment
Kaleido Biosciences Neutral
Movella Neutral

Company Net Margins Return on Equity Return on Assets
Kaleido BiosciencesN/A N/A N/A
Movella N/A N/A N/A

Movella has lower revenue, but higher earnings than Kaleido Biosciences. Movella is trading at a lower price-to-earnings ratio than Kaleido Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A
Movella-$559K-0.03-$220K-$0.62N/A

Kaleido Biosciences has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, Movella has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Summary

Movella beats Kaleido Biosciences on 4 of the 7 factors compared between the two stocks.

How does Kaleido Biosciences compare to Presto Automation?

Presto Automation (NASDAQ:PRST) and Kaleido Biosciences (NASDAQ:KLDO) are both small-cap computer software companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

Presto Automation has higher revenue and earnings than Kaleido Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Presto Automation$19.05M0.00-$34.48M-$1.23N/A
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A

In the previous week, Presto Automation's average media sentiment score of 0.00 equaled Kaleido Biosciences'average media sentiment score.

Company Overall Sentiment
Presto Automation Neutral
Kaleido Biosciences Neutral

Presto Automation has a beta of -3.45, meaning that its stock price is 445% less volatile than the broader market. Comparatively, Kaleido Biosciences has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Presto AutomationN/A N/A N/A
Kaleido Biosciences N/A N/A N/A

20.9% of Presto Automation shares are owned by institutional investors. Comparatively, 81.6% of Kaleido Biosciences shares are owned by institutional investors. 10.0% of Presto Automation shares are owned by company insiders. Comparatively, 9.0% of Kaleido Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Presto Automation beats Kaleido Biosciences on 4 of the 7 factors compared between the two stocks.

How does Kaleido Biosciences compare to Grafiti?

Grafiti (NASDAQ:DMN) and Kaleido Biosciences (NASDAQ:KLDO) are both small-cap computer software companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

Grafiti has a beta of 0.04, suggesting that its stock price is 96% less volatile than the broader market. Comparatively, Kaleido Biosciences has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

In the previous week, Grafiti's average media sentiment score of 0.00 equaled Kaleido Biosciences'average media sentiment score.

Company Overall Sentiment
Grafiti Neutral
Kaleido Biosciences Neutral

Grafiti has higher earnings, but lower revenue than Kaleido Biosciences. Grafiti is trading at a lower price-to-earnings ratio than Kaleido Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Grafiti$386.09K0.02-$45.95M-$84.00N/A
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A

Kaleido Biosciences has a net margin of 0.00% compared to Grafiti's net margin of -874.43%. Kaleido Biosciences' return on equity of 0.00% beat Grafiti's return on equity.

Company Net Margins Return on Equity Return on Assets
Grafiti-874.43% -1,561.96% -160.38%
Kaleido Biosciences N/A N/A N/A

11.7% of Grafiti shares are owned by institutional investors. Comparatively, 81.6% of Kaleido Biosciences shares are owned by institutional investors. 0.3% of Grafiti shares are owned by company insiders. Comparatively, 9.0% of Kaleido Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Kaleido Biosciences beats Grafiti on 7 of the 10 factors compared between the two stocks.

How does Kaleido Biosciences compare to iCoreConnect?

iCoreConnect (NASDAQ:ICCT) and Kaleido Biosciences (NASDAQ:KLDO) are both small-cap computer software companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

iCoreConnect has a beta of 33.29, suggesting that its share price is 3,229% more volatile than the broader market. Comparatively, Kaleido Biosciences has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

13.4% of iCoreConnect shares are held by institutional investors. Comparatively, 81.6% of Kaleido Biosciences shares are held by institutional investors. 59.4% of iCoreConnect shares are held by insiders. Comparatively, 9.0% of Kaleido Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, iCoreConnect's average media sentiment score of 0.00 equaled Kaleido Biosciences'average media sentiment score.

Company Overall Sentiment
iCoreConnect Neutral
Kaleido Biosciences Neutral

iCoreConnect has higher revenue and earnings than Kaleido Biosciences. iCoreConnect is trading at a lower price-to-earnings ratio than Kaleido Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iCoreConnect$11.05M0.00-$15.55M-$44.40N/A
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A

Kaleido Biosciences has a net margin of 0.00% compared to iCoreConnect's net margin of -263.12%. Kaleido Biosciences' return on equity of 0.00% beat iCoreConnect's return on equity.

Company Net Margins Return on Equity Return on Assets
iCoreConnect-263.12% -1,451.73% -171.32%
Kaleido Biosciences N/A N/A N/A

Summary

iCoreConnect and Kaleido Biosciences tied by winning 5 of the 10 factors compared between the two stocks.

How does Kaleido Biosciences compare to Grom Social Enterprises?

Kaleido Biosciences (NASDAQ:KLDO) and Grom Social Enterprises (NASDAQ:GROM) are both small-cap computer software companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Company Net Margins Return on Equity Return on Assets
Kaleido BiosciencesN/A N/A N/A
Grom Social Enterprises N/A N/A N/A

Kaleido Biosciences has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market. Comparatively, Grom Social Enterprises has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

81.6% of Kaleido Biosciences shares are held by institutional investors. Comparatively, 15.9% of Grom Social Enterprises shares are held by institutional investors. 9.0% of Kaleido Biosciences shares are held by company insiders. Comparatively, 0.0% of Grom Social Enterprises shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Grom Social Enterprises has higher revenue and earnings than Kaleido Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A
Grom Social Enterprises$3.72M0.00-$12.53M-$11.67N/A

In the previous week, Kaleido Biosciences' average media sentiment score of 0.00 equaled Grom Social Enterprises'average media sentiment score.

Company Overall Sentiment
Kaleido Biosciences Neutral
Grom Social Enterprises Neutral

Summary

Grom Social Enterprises beats Kaleido Biosciences on 4 of the 7 factors compared between the two stocks.

Get Kaleido Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLDO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KLDO vs. The Competition

Export
MetricKaleido BiosciencesBiotechnology IndustryMedical SectorNASDAQ Exchange
Market Cap$4K$443.68M$7.06B$12.20B
Dividend YieldN/A3.90%2.67%9.41%
P/E Ratio0.003.4927.1423.63
Price / SalesN/A6,592.41582.30111.98
Price / CashN/A13.1349.8158.78
Price / BookN/A83.7010.286.01
Net Income-$95.48M-$96.07M$3.60B$331.99M

Kaleido Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KLDO
Kaleido Biosciences
N/AN/AN/AN/A$4K$1.10MN/A80
MVLA
Movella
N/A$0.00
flat		N/AN/A$15K-$559KN/A3
PRST
Presto Automation
N/AN/AN/AN/A$10K$19.05MN/A4
DMN
Grafiti
N/A$0.00
flat		N/AN/A$8K$386.09KN/AN/A
ICCT
iCoreConnect
N/A$0.00
flat		N/AN/A$5K$11.05MN/A41

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:KLDO) was last updated on 7/26/2026 by MarketBeat.com Staff.
From Our Partners
Universal basic income is not impossible. It exist (kind of)
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
Oxford Club Analyst’s Urgent AI Warning
Alexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
The 90%-off options that empty accounts
A call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...
Profits Run | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
The Weekly Options Trick Wall Street Doesn't Advertise
The most profitable trading desks don't guess market direction, they collect income regardless of it. A 25-yea...
Base Camp Trading | Sponsoredtc pixel
Have you seen Elon’s new “supercurrency”? (It affects you)
Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...
StocksToTrade | Sponsoredtc pixel